Metronidazol B. Braun

Metronidazole, the active ingredient in Metronidazol B. Braun, is a nitroimidazole antibiotic presented as an intravenous solution for intravenous use. It is employed to treat anaerobic bacterial infections and certain protozoal diseases in adult patients, including intra‑abdominal infections, pelvic inflammatory disease and bacterial vaginosis.

GNH USA supplies Metronidazol B. Braun as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing for sterile injectable antibiotics.

Metronidazol B. Braun is a nitroimidazole antibiotic that targets anaerobic bacteria and susceptible protozoa. It is indicated for several established infections: - Intra‑abdominal infections: eradicates anaerobic organisms responsible for peritonitis and postoperative intra‑abdominal sepsis. - Pelvic inflammatory disease: treats mixed aerobic‑anaerobic infections of the upper genital tract. - Bacterial vaginosis: restores normal vaginal flora by eliminating Gardnerella and other anaerobes. - Amoebiasis: eliminates Entamoeba histolytica trophozoites in intestinal and extra‑intestinal disease.

Metronidazol B. Braun may cause a range of adverse reactions. Monitoring patients for both common and serious events is recommended.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Metallic taste: transient dysgeusia during infusion. - Headache: mild to moderate intensity. - Diarrhea: loose stools, usually self‑limited.

Serious or Rare Side Effects: - Seizures: rare neurologic events requiring immediate attention. - Peripheral neuropathy: tingling or numbness, potentially irreversible. - Severe allergic reactions: anaphylaxis, angioedema, or urticaria. - Stevens‑Johnson syndrome: extensive skin and mucosal involvement.

Before initiating therapy, clinicians should consider several safety factors. - Renal impairment: adjust dosing or monitor renal function closely. - Hepatic dysfunction: evaluate liver enzymes and consider dose modification. - Alcohol consumption: avoid during treatment and for 48 hours after to prevent disulfiram‑like reactions. - Pregnancy: prescribe only when benefits outweigh potential risks. - Concomitant metronidazole‑containing products: avoid duplicate therapy. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Metronidazol B. Braun can interact with several medicines; awareness helps prevent adverse outcomes.

Major Interactions (Avoid): - Alcohol: may cause severe disulfiram‑like reaction. - Warfarin: potentiates anticoagulant effect; monitor INR closely. - Lithium: can increase lithium concentrations; monitor serum levels.

Moderate Interactions (Monitor Closely): - Phenytoin: may reduce metronidazole levels, decreasing efficacy. - Cimetidine: may raise metronidazole concentrations, increasing toxicity risk.